Although epithelioid angiomyolipoma of the kidney has been studied by several groups, the reported prevalence of malignant behavior remains uncertain and there are not yet definitive predictive biomarkers. We evaluated the behavior of renal epithelioid angiomyolipoma in a consecutive series in a single institution and investigated the prognostic value of aberrant p53 expression and TFE3 gene abnormality.
Featured Article of the Month
Articles
-
-
Feasibility of fine needle aspiration for diagnosis of b-cell lymphoma of the thyroid: a case series and review of the literature
-
A suggested way forward for adoption of AI-Enabled digital pathology in low resource organizations in the developing world
-
Biased data, biased AI: deep networks predict the acquisition site of TCGA images
-
Pulmonary adenoid cystic carcinoma: molecular characteristics and literature review
-
Antinuclear antibodies and their detection methods in diagnosis of connective tissue diseases: a journey revisited
-
The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody
-
Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring
-
An unusual case of Acanthamoeba Polyphaga and Pseudomonas Aeruginosa keratitis
-
p16 as a diagnostic marker of cervical neoplasia: a tissue microarray study of 796 archival specimens
Featured Image of the Month
Global Advances in AI: Innovations in Digital Pathology and Radiology 2022
Kameda Medical Center (Japan), Nagasaki University (Japan) and The Ohio State University (USA) are teaming up to present a virtual joint conference on Global Advances in AI: Innovations in Digital Pathology and Radiology 2022. International speakers will share up-to-date information on AI development in pathology and radiology.
Latest Tweets
View Twitter timeline
Your browser needs to have JavaScript enabled to view this timeline
Artificial Intelligence in Cancer Imaging and Diagnosis
New tools and technologies such as computational and digital pathology, molecular diagnostics and artificial intelligence (AI) are making their way into advanced clinical diagnostics, providing some unique opportunities to incorporate these tools into the evolving health care landscape. We're proud to present a cross journal series with articles that would give the viewer a perspective of the current trends and future prospects of AI primarily in clinical diagnostics. Read here.
Dr Anil Parwani, Editor-in-Chief
"Diagnostic Pathology has emerged as a premier journal that aims to publish cutting edge articles focused on diagnostic pathology with an emphasis on novel morphological and molecular findings that make an impact on diagnosis of neoplastic and non-neoplastic diseases. The goal of the editorial board and our team is to highlight the cross-roads of diagnostic pathology and new tools and technologies that are exciting, challenging and making an impact on the practice of pathology. We will continue to bring updates in the field of diagnostic pathology by way of novel and interesting case reports, research and original articles and a series of key review articles by experts in the field that will emphasize the new developments which are disease-specific and highlight contemporary and novel technologies that are changing the practice of diagnostic pathology. This is an exciting time in pathology as we are confronted with a new frontier of science and technology which continues to evolve and accelerate the discipline of diagnostic pathology and we wish to take our readers with us on this exciting journey. We want to collaborate with our reviewers and our readers to make Diagnostic Pathology a premier and trusted source of new and exciting developments in the field of diagnostic pathology."
Dr Anil Parwani, Ohio State University
Annual Journal Metrics
-
Citation Impact
3.196 - 2-year Impact Factor (2021)
3.125 - 5-year Impact Factor (2021)
0.93 - Source Normalized Impact per Paper (SNIP)
0.805 - SCImago Journal Rank (SJR)Speed
65 days to first decision for all manuscripts (Median)
83 days to first decision for reviewed manuscripts only (Median)Usage
1,004,565 Downloads (2022)
367 Altmetric mentions (2021)